Xcout IntelNexalin Technology, Inc.
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Subscribe to see Nexalin Technology, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Nexalin Technology, Inc. at a glance
Nexalin Technology, Inc. is a medical devices company headquartered in Houston, United States. It is publicly listed (NXL) with a market capitalisation of $7.5M. Xcout tracks 16 named people at Nexalin Technology, Inc., including Mark White (President, Chief Executive Officer & Director).
Nexalin Technology, Inc. leadership
- Mark WhitePresident, Chief Executive Officer & Director
- Justin Van FleetChief Financial Officer
- David OwensChief Medical Officer, Member of Scientific Advisory Board & Director
- John Patrick ClaudeCo-Founder and Director of Engineering & Development
- Carolyn SheltonExecutive Vice President of Clinical, Quality & Regulatory Affairs
- Alan KazdenDirector
10 more named people on record for Nexalin Technology, Inc., with roles, board committees and tenure — see the full roster →
Nexalin Technology, Inc. competitors
A few of Nexalin Technology, Inc.'s closest competitors — see the full list of competitors and alternatives →
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
NeuroStar provides advanced, non-invasive transcranial magnetic stimulation (TMS) treatments designed for patients suffering from depression. The company is headquartered in Malvern, Pennsylvania, and offers physician-recommended in-office therapy.
Nalu Medical, Inc. is a privately held commercial medical device company based in Carlsbad, California. The company specializes in developing the Nalu neurostimulation system as a battery-free, long-term solution for chronic nerve pain.
NeuroGlove, LLC develops a novel medical device designed to treat a variety of neurological and psychological conditions, including stroke, Parkinson's disease, PTSD, traumatic brain injury, anxiety, depression, and insomnia. The company serves patients and healthcare sectors by providing innovative treatment options aimed at transforming healthcare.
NeuroEM Therapeutics develops non-invasive medical technology to treat Alzheimer's disease. The company utilizes Transcranial Electromagnetic Treatment with Radio Frequencies (TEMT-RF) to target toxic brain proteins associated with cognitive decline in patients.
NeuroThera develops a clinical-grade transcranial photobiomodulation platform that delivers near-infrared laser light to targeted brain regions. The company's non-invasive technology aims to treat major neurological and psychiatric conditions, including major depressive disorder, Alzheimer's disease, Parkinson's disease, traumatic brain injury, and stroke recovery.
Get Nexalin Technology, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Nexalin Technology, Inc. in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access